Skip to Main Content
Site Map
Table of Contents
Pages
Article Features
Clinical Trials
- 91-113 — Efficacy and pharmacokinetic/pharmacodynamic profile of ibuprofen chewable tablets versus ibuprofen suspension in febrile children. CSR 167S. Protocol 91-113, Unpublished Report 293A and Unpublished Report 1475.
- 97-024 — Multiple-Dose Pharmacokinetic Study of an Ibuprofen-Psuedoephedrine HCl Suspension in Children. Aug 1999.
- OBE/EPO-INT-02 — A clinical evaluation of the effect of maintaining haemoglobin levels with weekly EPREX®/ERYPO® (Epoetin alfa) in subjects with lymphoid malignancies (Hodgkin’s Disease, Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) undergoing chemotherapy
- RIS-USA-150 — A double-blind, placebo-controlled study of risperidone in children and adolescents with autistic disorder
- YP — A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children
- GAL-93-01 — A group comparative, placebo-controlled, double-blind trial of the efficacy and safety of galantamine hydrobromide, 7.5 mg (6 mg galantamine base) TID, 10 mg (8 mg galantamine base) TID and 15 mg (12 mg galantamine base) TID taken orally for 12 weeks in patients with a diagnosis of senile dementia of the Alzheimer’s type
- GAL-MVD-301 — A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease
- 30-49 — A Phase 3, Randomized, Open-Label, Comparative Study of DOXIL/CAELYX® versus Topotecan HCl in Patients with Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
- TOPMAT-PDMD-006 — A Randomized, Double-Blind, Multicenter, Placebo-Controlled, 21-Day Study of the Safety and Efficacy of Topiramate for the Treatment of Acute Manic or Mixed Episodes in Subjects With Bipolar I Disorder With an Optional Open-Label Extension
- RIS-USA-70 (EXTENSION OF RIS-USA-63) CR003361, RIS-USA-T216 — An open-label, long-term study of risperidone for the treatment of behavioral disturbances in patients with dementia
- GAL-CAN-5 — Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial
- RIS-INT-83 — Efficacy and safety of a flexible dose of risperidone versus placebo in the treatment of psychosis of Alzheimer’s disease. A double-blind, placebo-controlled, parallel-group study.
- C0168T16 — Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
- EPO-2 /// PR98-15-014 — Efficacy in the rHuEPO (Epoetin Alfa) in the Critically Ill Patient: A Randomized, Double Blind, Placebo-Controlled trial
- GAL-MVD-302 — Galantamine treatment of vascular dementia: a randomized trial
- 12053 — Graded Exercise Therapy guided SElf-help Treatment (GETSET) for patients with chronic fatigue syndrome/myalgic encephalomyelitis: a randomised controlled trial in secondary care
- GAL-INT-3 — Long Term Safety and Efficacy of Galantamine in the treatment of Alzheimer's Disease
- GAL-INT-7 — Long Term Safety and Efficacy of Galantamine in the treatment of Alzheimer's Disease
- C0168T20 — A Placebo-controlled, Repeated-dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients with Enterocutaneous Fistulae as a Complication of Crohn’s Disease
- CR002392/LOFBIV-PCAP-003 — A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard of Care Therapy in the Treatment of Children With Community-Acquired Pneumonia in the Hospitalized or Outpatient Setting
- RIS-USA-231 — The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone
- RIS-USA-232/CR002764 — Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease
- RIS-USA-259 — Open-Label Trial Exploring A Switching Regimen From Oral Neuroleptics, Other Than Risperidone, To Risperidone Depot Microspheres
- TOPMAT-PDMD-008 — A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study of the Safety and Efficacy of Topiramate in Patients With Acute Manic or Mixed Episodes of Bipolar I Disorder With an Optional Open-Label Extension
- TOPMAT-PDMD-009 — A Randomized, Double-Blind, Multicenter, Placebo-Controlled 4-Week Study of the Safety and Efficacy of Topiramate in Adolescents With Acute Manic or Mixed Episodes of Bipolar I Disorder, With an Optional 6-Month Open-Label Extension
- C0168T32 — A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis
- C0168T41 — A Randomized, Double-blind Trial of the Safety of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis on Standard Disease-modifying Anti-Rheumatic Drug
- C0168T37 — A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
- TOPMAT-PDMD-004 — A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study of the Safety and Efficacy of Two Doses of Topiramate for the Treatment of Acute Manic or Mixed Episodes in Patients With Bipolar I Disorder With an Optional Open-Label Extension
- RIS-INT-93 — A Study to Evaluate the Efficacy, Safety and Maintenance Effect of Risperidone Augmentation of SSRI Monotherapy in Young and Older Adult Patients With Unipolar Treatment-Resistant Depression
- C0168T60 — A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Anti-TNF a Monoclonal Antibody (Infliximab) to Treat Cancer-Related Cachexia in Subjects With Pancreatic Cancer
- ET743-STS-201 — A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide
- RIS-SCP-402 — A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
- AC-052-330 (BUILD 2) — A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis
- TMC114-C202 — A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose Response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV
- AC-052-320 (BUILD 1) — A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension
- C0168T48 — A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement
- R092670-SCH-201 — A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 Mg-eq of Paliperidone Palmitate in Patients With Schizophrenia
- RIS-BIM-301 — Research on the Effectiveness of Risperidone in Bipolar Disorder in Adolescents and Children (REACH): A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Risperidone for the Treatment of Acute Mania in Bipolar I Disorder
- AC-052-331 — A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic Sclerosis
- R076477-SCH-304 — A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of Paliperidone Extended Release Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia
- R076477-SCH-303 — Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
- GAL-ALZ-303 — Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease
- R076477-SCH-305 — A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (ER) Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia
- R076477-SCH-302 — A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Paliperidone Extended Release in the Treatment of Geriatric Patients With Schizophrenia
- RIS-ANX-301 — A Double-blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-optimally Responsive to Standard Psychotropic Therapy
- R076477-SCH-301 — A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Evaluating Paliperidone Extended Release Tablets in the Prevention of Recurrence in Subjects With Schizophrenia
- RIS-SCH-302/CR003370 — A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents
- AC-052-364 — A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension (PAH)
- CR004114 (EPO-ICU-002) — A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Epoetin Alfa in Critically Ill Subjects
- C0168T67 — Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE® (infliximab) and REMICADE plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn’s Disease Naive to both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Crohn’s Disease)
- RIS-BIP-302 — A Prospective, Randomized, Double-blind, Placebo-controlled Study of the Effectiveness and Safety of RISPERDAL CONSTA Augmentation in Adult Patients With Frequently-relapsing Bipolar Disorder
- RIS-DEP-401 — A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is not Responding to Standard Therapy
- C0168T46 — A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
- R092670PSY3004 — A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia
- R076477-SCH-1010/CR002281 — A Double-blind, Placebo-controlled, Randomized Study Evaluating the Effect of Paliperidone ER Compared With Placebo on Sleep Architecture in Subjects With Schizophrenia
- CR003130 / C0168T38 — A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction and Maintenance Therapy in Patients With Moderate to Severe Plaque Psoriasis
- R092670PSY3001 — A Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion
- TOPMATPEP3001 — A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures
- R092670PSY3005 — A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Patients With Schizophrenia
- RISBIM3003 — A Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension
- C0168T21 — ACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease
- C0168T47 — A Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF a Chimeric Monoclonal Antibody (Infliximab, REMICADE) in Pediatric Subjects With Moderate to Severe CROHN'S Disease
- C0168T51 — A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy
- C0524T02 — A Randomized, Double-blind, Dose-ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate
- C0743T06 — A Phase II, Double-blind, Placebo-Controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40(CNTO1275) in Subjects With Relapsing-remitting Multiple Sclerosis
- C0524T03 — A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma
- C0168T26 — ACCENT II - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN'S Disease
- CAPSS-334 — Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate)
- TOPMATMIG3006 — A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for the Prophylaxis of Migraine in Pediatric Subjects 12 to 17 Years of Age
- R092670PSY3003 — A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (50 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia
- PR04-15-001 — A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of Recombinant Human Erythropoietin (Epoetin Alfa (PROCRIT®)) on Functional Outcomes in Anemic, Critically Ill, Trauma Subjects
- ET743-SAR-3002 — A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
- R092670PSY3002 — A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia
- CAPSS-272 — A Double-blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects With Seizures Indicative of New Onset Epilepsy
- CAPSS-220 — A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
- CAPSS-277 — A Comparison of Topiramate Versus Amitriptyline in Migraine Prophylaxis
- CAPSS-296 — An Open-label Study of the Safety and Efficacy of Topiramate for Migraine Prophylaxis: Extension Study to CAPSS-277
- CAPSS-349 — A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
- CAPSS-276 — A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Chronic Migraine
- CAPSS-278 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence
- PR00-06-014 — Correction of Hemoglobin and Outcomes In Renal Insufficiency (CHOIR)
- CR004414 (EPO-INT-76) DOUBLE BLIND — A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects Receiving Chemotherapy
- PR97-19-002 — An Open-Label, Randomized, Parallel-Group Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Subjects Undergoing Major Elective Spinal Surgery
- CAPSS-381 (INTREPID) — TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study
- RISSCH3001 — CONSTATRE: Risperdal® Consta® Trial of Relapse Prevention and Effectiveness
- GAL ITA-2 — Long Term Treatment With Galantamine In Dementia
- RIS-KOR-66 — A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)
- RIS-PSY-301 — An Open-label Trial of Risperidone Long-acting Injectable in the Treatment of Subjects With Recent Onset Psychosis
- GAL-ALZ-302 (PMID # 19042161-CR003940) — Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study
- TOPMAT-MIG-201 — A Randomized Double-Blind Placebo Controlled Trial to Investigate the Efficacy and Tolerability of Topiramate in the Prophylaxis of Chronic Migraine
- TOPMAT-MIG-303 — A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Tolerability of Topiramate in Prolonged Migraine Prevention
- RISSCH4026 — Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR)
- RISSCH4045 — Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode
- CR003124 / C0168T31 — A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab (REMICADE) Induction Therapy in Patients With Plaque-type Psoriasis
- TOPMAT-EPMN-104 — Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures
- TOPMAT-OBDM-003 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients on a Controlled Diet
- TOPMAT-EPMN-106 — A Randomized, Double-Blind, Parallel-Group, Monotherapy Study to Compare the Safety and Efficacy of Two Doses of Topiramate in the Treatment of Newly Diagnosed or Recurrent Epilepsy
- TOPMAT-MIGR-002 — A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine
- TOPMAT-OBMA-001 — The Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity: A 6-Month Double-Blind, Randomized, Placebo-Controlled Study With a 6-Month Open-Label Extension
- TOPMAT-OBDL-001 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, One-year Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Subjects With Dyslipidemia
- TOPMAT-OBDM-004 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy
- TOPMAT-OBD-202 — A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Assess the Efficacy and Safety of Topiramate OROS Controlled-Release in the Treatment of Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin
- TOPMAT-OBDM-002 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients Treated With Metformin
- TOPMAT-NP-005 — A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Topiramate on Electrophysiological Parameters in Subjects With Diabetic Peripheral Polyneuropathy
- C0168T29 — A Randomized, Double-blind, Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared With Methotrexate Alone for the Treatment of Patients With Early Rheumatoid Arthritis
- RIS-USA-305 — An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder
- RIS-USA-275 — A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder
- YTCE — Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures
- GAL-INT-18 — A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease
- CR002020 (RIS-INT-79) — Risperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
- RIS-INT-62 — Randomized, Multi-center, Open Label Trial Comparing Risperidone Depot (Microspheres) and Olanzapine Tablets in Patients With Schizophrenia or Schizoaffective Disorder
- CR002149 (RIS-INT-84) — Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders - an Open Label Follow-up Trial of CR002020
- TOPMAT-MIGR-001 — A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine
- TOPMAT-MIGR-003 — A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine
- CR003145 // GAL-INT-11 — A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease
- RIS-USA-265 — An Open Label, Long Term Trial of Risperidone Long Acting Microspheres in the Treatment of Patients Diagnosed With Schizophrenia
- TOPMAT-OBES-004 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of Topiramate in Weight Loss Maintenance in Obese Patients Following Participation in an Intensive, Non-Pharmacologic Weight Loss Program
- TOPMAT-OBES-001 — A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
- TOPMAT-OBDM-001 — A 9 Month, Double-Blind, Placebo-Controlled Study With a Blinded Crossover Transition to Open-Label Extension, Evaluating the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Type 2 Diabetes Patients
- TOPMAT-OBES-002 — A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity
- TOPMAT-OBHT-001 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension
- YTC — Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures
- YD — Double-Blind Parallel Comparison of Three Doses of Topiramate and Placebo in Refractory Partial Epilepsy
- YL — A Double-Blind Trial of Topiramate in Subjects With Lennox-Gastaut Syndrome.
- NRGEEP-CONT-002 — An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17deacetyl-norgestimate and Ethinyl Estradiol
- Y2 — Double-Blind, Parallel Comparison of Topiramate 300 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy
- Y3 (CC2604-C-103) — Double-Blind Parallel Comparison of Topiramate 400 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy
- Y1 (CC2604-C-101) — Double-Blind Parallel Comparison of Topiramate 200 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy
- CR002653 (CAPSS-168) — Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting
- CAPSS-122 — A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Migraine in Pediatric Subjects
- TOPMAT-PDMD-005 (CR002248) — A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study Of The Safety And Efficacy Of Two Doses Of Topiramate For The Treatment Of Acute Manic Or Mixed Episodes In Subjects With Bipolar I Disorder With An Optional Open-Label Extension
- 42603ATT3002 — A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate the Safety And Efficacy Of Prolonged Release OROS Methylphenidate Hydrochloride (18, 36 and 72 mg/Day), With Open-Label Extension, In Adults With Attention Deficit/Hyperactivity Disorder
- 42603MDD3001 (CON-CAN-3) — A Double-blind, Placebo-controlled, Randomized Trial to Evaluate the Safety, Tolerability and Efficacy of CONCERTA® (Methylphenidate Hydrochloride) Augmentation of SSRI/SNRI Monotherapy in Adult Patients With Major Depressive Disorder.
- RIS-BIP-301 — A Randomized, Open-label Trial of RISPERDAL® CONSTA™ Versus Oral Antipsychotic Care in Subjects With Bipolar Disorder
- RIS-INT-3 — A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
- RIS-INT-24/CR006046 — Risperidone in the Treatment of Behavioral Disturbances in Demented Patients: an International, Multicenter, Placebo-controlled, Double-blind, Parallel-group Trial Using Haloperidol as Internal Reference
- RIS-AUS-5/CR006010 — Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial
- RIS-INT-61 — Risperidone Depot (Microspheres) vs. Risperidone Tablets - a Non-inferiority, Efficacy Trial in Subjects With Schizophrenia
- RIS-IND-2/CR006064 — The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder
- CR006007 (RIS-CAN-19) — The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years
- RIS-INT-46/CR006058 — The Safety And Efficacy Of Risperdal (Risperidone) Versus Placebo As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder
- RIS-USA-63/CR006022 — A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia
- RIS-USA-121/CR006055 — Risperidone Depot (Microspheres) vs. Placebo in the Treatment of Subjects With Schizophrenia
- RIS-USA-102/CR006040 — The Safety And Efficacy Of Risperdal (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder
- RIS-INT-69 — The Efficacy And Safety Of Flexible Dose Ranges Of Risperidone Versus Placebo Or Haloperidol In The Treatment Of Manic Episodes Associated With Bipolar I Disorder
- CAPSS-155 — A Comparison Of The Efficacy And Safety Of Topamax® (Topiramate) Tablets Versus Placebo For The Prophylaxis Of Migraine
- GAL-INT-1 — Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease
- GAL-USA-1 — Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease
- GAL-INT-10 — Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
- GAL-INT-2 — Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial
- RIS-USA-239/CR006052 — The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Episodes Associated With Bipolar I Disorder
- TMC114-C211 — Phase III Randomized, Controlled, Open-label Trial to Investigate the Antiviral Activity, Tolerability and Safety of TMC114/r in Treatment- Naive HIV-1 Infected Patients
- RIS-CAN-23/CR006106 — Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study
- GAL-INT-6 — The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia
- C0524T05 — A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously, in Methotrexate-naïve Subjects with Active Rheumatoid Arthritis
- C0524T06 — A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy
- C0524T09 — A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Ankylosing Spondylitis
- C0524T08 — A Multicenter, Randomized, Double-blind, Placebo controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Psoriatic Arthritis
- C0379T07 — A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn's Disease
- CR006019 (RIS-USA-93) — The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years
- I88-037 — The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Chemotherapy
- C0743T10 — A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
- C0743T08 — A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
- C98012 — Long-term Safety and Effectiveness of OROS (Methylphenidate HCl) in Children With ADHD
- C0168T16 — A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease
- C0168T22 — A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment
- RIS-KOR-64 — Effect on Efficacy, Safety and Quality of Life by Long-Term Treatment of Long-Acting Risperidone Microspheres in Patients With Schizophrenia
- I88-036 — The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Cisplatin Chemotherapy
- CR005905 (J89-040) — The Effect of Subcutaneous r-HuEPO in Patients With Chronic Lymphocytic Leukemia
- CR005911 (EPO-INT-2) — A Placebo-Controlled Study on the Effect of r-huEPO in Patients With Multiple Myeloma Followed by an Open-Label Extension
- CR005917 (EPO-INT-10) — Double-Blind, Placebo-Controlled Study to Assess the Effect of Early Intervention and/or Treatment With Epoetin Alfa on Anemia in Cancer Patients Receiving non-Platinum-Containing Chemotherapy
- CR005923 (EPO-INT-3) — A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy
- CR006076 (I88-009) — A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
- RIS-SCH-401 — A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (RISPERDAL CONSTA) in Adults With Schizophrenia or Schizoaffective Disorder
- C0524T11 — A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis and Previously Treated with Biologic Anti TNFa Agent(s)
- RISSCH4060 — A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in Adults With Schizophrenia
- R076477-BIM-3001 — A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-Release Paliperidone in the Treatment of Subjects With Acute Manic and Mixed Episodes Associated With Bipolar I Disorder
- AC-052-414 (COMPASS-2) — Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study
- GAL-USA-3 — Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8)
- C0743T09 — A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
- 42603ATT3004 — An Open International Multicentre Long-Term Follow Up Study to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder
- R076477-BIM-3003 — A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone as Adjunctive Therapy to Mood Stabilizers in the Treatment of Acute Manic and Mixed Episodes Associated With Bipolar I Disorder
- R076477-BIM-3002 — A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed, Extended-Release Paliperidone Compared With Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute Manic and Mixed Episodes Associated With Bipolar I Disorder
- AC-052-366 — Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- 05-HEALOS-01 — A Prospective, Multicenter, Randomized Study Comparing the Use of HEALOS® to Autograft in a Transforaminal Lumbar Interbody Fusion (TLIF) Approach
- C0168T61 — Open-label, Pilot Protocol of Patients with Rheumatoid Arthritis Who Switch to Infliximab after Incomplete Response to Etanercept
- AC-052-367 — An Open Label, Long-term, Safety, and Tolerability Extension Study Using the Pediatric Formulation of Bosentan in the Treatment of Children With Idiopathic or Familial Pulmonary Arterial Hypertension Who Completed FUTURE 1
- AC-052-332 (BUILD 2 OL) — Long-term Open-label Study in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis Who Completed the Protocol AC-052-330
- AC-052-370 (BENEFIT OL) — Long-term Open-label Extension Study in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Who Completed Protocol AC-052-366 (BENEFIT)
- AC-052-365 — An Open Label, Multicenter Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Pediatric Formulation of Bosentan in Children With Idiopathic or Familial Pulmonary Arterial Hypertension
- AC-052-333 (RAPIDS-2 OL) — Long-term Bosentan Open Label Extension of the AC-052-331 Study in Systemic Sclerosis Patients With Ischemic Digital Ulcers
- C0379T04 — A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis
- 12-304 — An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder
- 02-159/CR011560 — A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate the Efficacy and Safety of CONCERTA (Methylphenidate HCl) Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg Per Day
- R076477SCH3015 — A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Paliperidone ER Compared to Quetiapine in Subjects With an Acute Exacerbation of Schizophrenia
- C0168T72 — A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis
- TMC114-C212 — A Phase II, Open-label Trial, to Investigate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of TMC114/Rtv b.i.d in Treatment-Experienced HIV-1 Infected Children and Adolescents
- C0524T12 — A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy
- RISSCH4043 — Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta?
- CR011992, RISSCH3024 — A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia
- RISBMN3001 — A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder
- AC-052-321 — Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study
- R076477SCA3001 — A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dosages of Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder
- R076477SCA3002 — A Randomized, Double-blind, Placebo-controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Flexible-dose Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder
- AC-052-419 — COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-Minute Walk Test (6-MWT) Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of Magnetic Resonance Imaging (MRI) on Cardiac Remodeling
- CR011929, TMC207-TIDP13-C208, 2007-004462-40 — A Phase II, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Subjects With Newly Diagnosed Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).
- C0743T12 — A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis
- R076477SCH3017 — An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia
- COU-AA-001 — A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy
- COU-AA-002 — Phase I/II Open Label Dose Escalation Study of the 17α-Hydroxylase/ C17,20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer
- COU-AA-003 — A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
- COU-AA-004 — A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
- C0524T17 — A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis
- R076477PSZ3002 — A 2-Year, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5-12 mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) With Schizophrenia
- C0524T18 — A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
- C0524T16 — A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
- R076477BIM3004 — A Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated With Bipolar I Disorder
- RIS-INT-80 — Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open-label Follow-up Trial of RIS-INT-62 and RIS-INT-85
- R076477PSZ3001 — A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
- TMC207-C202 — An Open-label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of TMC207 in Treatment-naive Subjects With Sputum Smear Positive Pulmonary Tuberculosis.
- R076477SCH4012 — A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed Dosage of 1.5 mg/Day of Paliperidone Extended Release (ER) in the Treatment of Subjects With Schizophrenia
- RISSCH4119 (RISC-TWN-MA10) — Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-acting Risperidone Microspheres
- TMC278-TIDP6-C209 — A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects
- TMC278-TIDP6-C215 — A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects.
- COU-AA-BMA — An Observational Study of Continuous Oral Dosing of an Irreversible CYP17 Inhibitor, Abiraterone Acetate (CB7630), in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
- C0168Z01 — Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry
- R076477SCH3018 — Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia
- ELN115727-301 — A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers
- 54767414GEN501 — Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study
- ELN115727-302 — A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers
- RISAUT4002 — Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety
- ET-B-028-06 — Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
- R092670PSY3006 — A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia
- R092670PSY3007 — A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia
- R092670PSY3008 — A Randomized, Open-Label, Parallel Group Comparative Study of Paliperidone Palmitate (50, 100, 150 mg eq) and Risperidone LAI (25, 37.5, or 50 mg) in Subjects with Schizophrenia
- AC-052-322 — Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
- COU-AA-301 — A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
- 28431754DIA2001 — A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm
- R076477SCH3020 — A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia
- GAL-CHN-T100 — A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer's Disease:Safety and Effectiveness of an Immediate-release Table Formulation.
- R076477-SCH-701 — A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS® Paliperidone in the Prevention of Recurrence in Subjects With Schizophrenia - Open Label Phase
- R076477-SCH-703 — A Randomized, DB, PC and AC, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS Paliperidone (6, 9, 12 mg/Day) and Olanzapine (10 mg/Day), With Open-Label Extension, in the Treatment of Subjects With Schizophrenia - Open Label Phase
- 28431754OBE2001 — A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects
- TMC114-C213 — A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Subjects, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV
- 30-57 — A Phase 3, Randomized, Open-Label, Comparative Study of CAELYX® versus Paclitaxel HCl in Patients with Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
- RAB-M-A003 — A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects
- AC-055-302 — A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
- R076477-SCH-705 — Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia
- GALALZ3005 — A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease
- RAB-M-A004 — A Single-blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-exposure Prophylaxis in Children and Adolescents
- 42603ATT3013 — A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder
- JNS009-JPN-02 — A Placebo-Controlled Double-Blind Comparative Study of CNTO1275 in Patients With Plaque Type Psoriasis
- NRGMONCON4002 — An Open Label Study to Evaluate Cycle Control with Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) and Yaz (drospirenone/ethinyl estradiol) in Healthy Sexually Active Females
- C0743T25 — A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
- R076477-SCH-702 — 24 week extension of NCT00085748: A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Paliperidone Extended Release in the Treatment of Geriatric Patients With Schizophrenia
- C0743T26 — A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy
- ET743-OVC-1001 — A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
- ET-C-002-07 — An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
- CONCERTA-ATT-4069 — The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children With ADHD
- CONCERTA-ATT-4080 — Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral and Cognitive Effects of CONCERTA on Older Children With ADHD (The ABC Study)
- VISSIT CA-2007-01 — Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease
- RIS-SCH-1012 — Single-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Patients With Chronic Stable Schizophrenia
- CR008329 (12-101) — A Multi-center Randomized Parallel Group Study Evaluating Treatment Outcomes of Concerta (Extended Release Methylphenidate) and Strattera (Atomoxetine) in Children With Attention-deficit/Hyperactivity Disorder
- COU-AA-302 — A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- AC-055B201 — A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis
- CR012352, TMC207-TiDP13-C209, 2008-008444-25 — A Phase II, Open-label Trial With TMC207 as Part of a Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Subjects With Sputum Smear-positive Pulmonary Infection With MDR-TB
- TMC114-TiDP29-C230 — A Phase II, Open-Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Drv/Rtv Once Daily in Treatment-Naive HIV-1 Infected Adolescents Aged Between 12 and < 18 Years
- TMC114-TiDP29-C228 — A Phase II, Open Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of DRV in Combination With Low-Dose Ritonavir (DRV/Rtv) in Treatment-Experienced HIV-1 Infected Children From 3 Years to Below 6 Years of Age
- COU-AA-201-DFCI — A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer
- CR015058 (CONCERTA-ATT-3014 ) — A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate
- 1275148SCD2001 — A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis
- 28431754DIA3009 — A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy
- CNTO148ART3001 — A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
- RISSCH4178 — A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder
- CNTO148ART3002 — Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
- C0743T23 — A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis
- R076477PSZ3003 — A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
- CNTO1275PSA3001 /// PSUMMIT I — A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
- AC-052-281 — A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of Bosentan in Patients With Stage IV Metastatic Melanoma Treated With Dacarbazine
- 28431754DIA3008 — A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
- RISNAP4022 — Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
- R092670SCH3009 — Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics
- CNTO1275PSO4004 — An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitiioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT)
- 28431754DIA3004 — A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
- CNTO1275PSA3002 /// PSUMMIT II — A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
- R092670SCH3005 — A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia
- 28431754DIA3005 — A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
- COU-AA-203 — A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone
- CNTO1275PSO3006 — A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the of Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type Psoriasis (CADMUS)
- PCYC-1102-CA — A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
- AC-065A302 — A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension
- 28431754DIA3002 — A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy
- 28431754DIA3010 — A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
- 28431754DIA3006 — A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
- 28431754DIA3012 — A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy
- 28431754DIA3015 — A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy
- MINALO3004 — A Phase 3, Multi-Center, Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam versus 2% Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia)
- KOXDHY0003 — Determination of the oral irritation and sensitization potential of two experimental potassium oxalate containing mouth rinses
- R092670SCH3006 — A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated
- MEBENDAZOLGAI3002 — An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive
- REMICADECRD3001 — Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
- R092670SCA3004 — A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
- AC-052-373 — An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension
- MINALO3005 — A Phase 3, Multi-Center, Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam versus vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia)
- RAB-M-A008 — A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects
- CNTO148JIA3001 — A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
- PCYC-1104-CA — Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
- C0524T28 — A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy
- C0524T29 — A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects with Ankylosing Spondylitis
- PALM-JPN-5 — A Long-Term, Open-Label Study of Flexibly Dosed Paliperidone Palmitate Long-Acting Intramuscular Injection in Japanese Patients With Schizophrenia
- R092670SCH3010 — A 6-month, Open Label, Prospective, Multicenter, International, Exploratory Study of a Transition to Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated With Oral or Long-acting Injectable Antipsychotics
- PALM-JPN-4 — A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
- 212082PCR2005 — A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
- JNS001-JPN-A01 — A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day
- AC-052-374 — A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension
- 28431754DIA2003 — A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
- ET743-SAR-3007 — A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
- KOXDHY0005 — Assessment of a potassium oxalate containing formulation for the relief of dentinal sensitivity
- CNTO1275CRD3001 — A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
- CNTO1275CRD3002 — A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
- CNTO1275CRD3003 — A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease
- 212082BCA2001 — Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
- 28431754DIA3014 — A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 18-Week Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
- Smart-AF — THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
- EPOANE4008 — A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects With Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia
- 212082PCR2008 — An Open-Label Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Subjects With Metastatic Castration-Resistant Prostate Cancer
- P07642 — A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Also Known as MK-8259-006-02)
- NRGMONCON4003 — Comparative Study of the Effect on Acne With norgestimate Containing Triphasic Oral Contraceptive and Biphasic Preparation Containing Desogestrel
- AC-055C301 — Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
- AC-055C302 — Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
- CNTO1959PSO2001 — A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE)
- 39758979ADM2001 — A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-39758979 in Adult Japanese Subjects with Moderate Atopic Dermatitis
- R092670PSY3011 — A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
- R092670SCH4009 — An Open-Label, Prospective, Non-Comparative Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia
- R092670PSY3012 — A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects With Schizophrenia
- CNTO1275PSO3009 — A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
- CR018769; REMICADEUCO3001 — A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Infliximab in Chinese Subjects With Active Ulcerative Colitis
- R092670PSY1005 — A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia
- PCYC-1112-CA — A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- ABI-PRO-3002 — A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- CNTO136ARA3002 — A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite DMARD Therapy
- R076477SCH3033 — An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly-Dosed Paliperidone ER among Treatment-Naive and Newly Diagnosed Patients with Schizophrenia
- CNTO136ARA3003 — A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy
- PCI-32765CLL3001 — Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- 54767414GEN503 — An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
- RIS-AUT-JPN-01 — A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder
- KETIVTRD2002 — A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
- ESKETIVTRD2001 — A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects With Treatment-Resistant Depression
- 300101 — Sacroiliac Joint Fusion with iFuse Implant System (SIFI)
- CNTO1275ARA2001 — A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy and Safety of Ustekinumab (STELARA®) and CNTO 1959 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy
- PCI-32765MCL3001 — A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
- R076477-SCH-3041 — Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
- 300103 — INSITE Investigation of Sacroiliac Fusion Treatment
- 212082PCR2007 — A Phase 2 Open Label Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy.
- CNTO136ARA3001 — A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
- ABI-PRO-3001 — A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
- 212082PCR3011 — A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)
- PCYC-1115-CA — Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- KOXDHY0008 — Evaluation of an experimental mouth rinse device for relieving dentinal hypersenstivity
- 300134 — iMIA: iFuse Implant System® Minimally Invasive Arthrodesis
- AC-055-305 — A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
- PCI-32765MCL3002 — A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
- ARN-509-002 — The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
- JNJ-212082-JPN-202 — A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration-Resistant Prostate Cancer Patients Who Have Received Docetaxel-based Chemotherapy
- 28431754DIA3011 — A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
- RISSCH4186 — Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone
- PCI-32765DBL3001 — A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
- CNTO148UCO3001 — A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis
- TEROV8BAC4001 — A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic)
- 212082PCR2023 — A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naïve and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients
- TMC125VIR1001 — A Phase I, Partially Randomized, Open Label, Two-way, Two Period Cross-over Study to Investigate the Pharmacokinetic Interaction Between Etravirine or Darunavir/Rtv and Artemether/Lumefantrine at Steady-state in Healthy HIV-negative Subjects
- ARN-509-003 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
- CNTO148ART3003 — A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
- 54767414MMY2002 — An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a Proteasome Inhibitor and an IMiD
- CNTO148UCO2001 — A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
- 28431754DIA4003 — A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus
- ESKETINTRD2003 — A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)
- 54767414MMY1001 — An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma
- CNTO136ARA3005 — A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA® Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis
- 28431754DIA4004 — A Randomized, Double-blind, Placebo Controlled, 2-arm, Parallel-group, 26-week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin Therapy
- MEBENDAZOLGAI3003 — A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects
- 28431754DNE3001 — A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
- AC-055G201 — A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction
- 54767414MMY3003 — Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
- KOXDHY0009 — Assessment of potassium oxalate containing formulation for the relief of dentinal hypersenstivity
- ESKETINSUI2001 — A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Imminent Risk for Suicide
- 54767414MMY3004 — Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma
- PCYC-1127-CA — iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia
- CNTO148PSA3001 — A Study of Golimumab in Participants With Active Psoriatic Arthritis
- CNTO148AKS3001 — A Study of Golimumab in Participants With Active Ankylosing Spondylitis
- 54767414MMY3007 — A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
- PCYC-1129-CA — A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease
- CNTO1959PSO3003 — A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
- CNTO1959PSO3001 — Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
- CNTO1959PSO3002 — A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment
- 212082PCR4001 — A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer
- 28431754OBE2002 — A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Efficacy of the Co-administration of Canagliflozin 300 mg and Phentermine 15 mg Compared With Placebo for the Treatment of Non-diabetic Overweight and Obese Subjects
- 54767414MMY3008 — A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
- 56021927PCR3001 — A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
- AC-065C202 — A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
- PCYC-1130-CA — A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- TMC114IFD3013 - WK48 — A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects
- TMC114IFD3013 - WK48 — A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects
- 300244 — Long-Term Follow-Up in INSITE/SIFI (LOIS)
- 38518168PSO2001 — A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled, Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
- CNTO1959PSO3004 — A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
- AC-055-404 — A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
- MEBENDAZOLGAI3001 — Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population
- CNTO1275AKS3003 — A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis
- CNTO1275UCO3001 — A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
- ESKETINTRD3001 — A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
- ESKETINTRD3002 — A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
- ESKETINTRD3005 — A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression
- TMC114FD2HTX3001 - WK48 — A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects
- TMC114FD2HTX3001 - WK48 — A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects
- CNTO1275AKS3001 — A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF Alpha Naive Subjects With Active Radiographic Axial Spondyloarthritis
- CNTO1275AKS3002 — A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis
- AC-065A304 — Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension
- 56022473AML2002 — A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy
- 56021927PCR3002 — A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- ESKETINTRD3003 — A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression
- ESKETINTRD3004 — An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
- CNTO1275PSO3013 — A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Subjects Greater Than or Equal to 6 to Less Than 12 Years of Age
- CNTO1275PSO3013 — A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Subjects Greater Than or Equal to 6 to Less Than 12 Years of Age
- R092670SCH3015 — A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
- CNTO148DML2001 — SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
- CNTO1959PSO3006 — A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered Via a SelfDose (TM) Device in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis
- 54135419TRD2005 — A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression
- CNTO1959PSO3008 — Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded, Active Comparator-Controlled Phase 3b Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters (Fumaderm Initial/ Fumaderm) for Adult Patients With Moderate to Severe Plaque Psoriasis Who Are Candidates for and Naive to Systemic Treatment
- 54767414MMY2012 — Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma
- 54135419SUI3002 — A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide
- AC-065A404 — A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts
- CNTO1959PSO3009 — A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
- 54135419SUI3001 — A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide
- 300243 — Study of Bone Growth in the Sacroiliac Joint After Minimally Invasive Surgery With Titanium Implants (SALLY)
- 54767414MMY3013 — A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor
- 28431754DIA4026 — Canagliflozin Continuous Glucose Monitoring (CANA CGM) Trial: A Pilot Randomized, Double-Blind, Controlled, Crossover Study on the Effects of the SGLT-2 Inhibitor Canagliflozin (vs. the DPP-4 Inhibitor Sitagliptin) on Glucose Variability in Mexican Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
- 54767414MMY3012 — A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
- R092670PSY3015 — A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation
- AC-055-122 — A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of Macitentan at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects.
- 54767414MMY2040 — A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
- ESKETINTRD3006 — A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
- ESKETINTRD3006 — A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
- CNTO1275CRD3007 — A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn's Disease
- CNTO1275SLE3001 — A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus
- 68284528MMY2001 — A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
- CNTO1959HDS2001 — A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa
- ESC-2018-01 — A Videographic Study to Evaluate the Impact of a Pulsed Firing Technique on Staple Line Interventions in Laparoscopic Sleeve Gastrectomy
- 77474462HDS2002 — A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa
- 77474462ADM2002 — A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
- 53718678RSV2006 — A Two-Part Study With a Birth Cohort (Observational Stage) for Early Diagnosis of Respiratory Syncytial Virus (RSV), Followed by an Optional Phase 2a, Randomized, Double-blind, Placebo-controlled Study (Interventional Stage) to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 in Infants With Acute Respiratory Tract Infection Due to RSV
- 53718678RSV2006 — A Two-Part Study With a Birth Cohort (Observational Stage) for Early Diagnosis of Respiratory Syncytial Virus (RSV), Followed by an Optional Phase 2a, Randomized, Double-blind, Placebo-controlled Study (Interventional Stage) to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 in Infants With Acute Respiratory Tract Infection Due to RSV
- VAC31518COV1001 — A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older
- VAC31518COV3001 — A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
- VAC31518COV3009 — A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
- AC-056C501 — NPC Registry (AC-056C501) Registry is an international, multi-center, prospective, observational, long-term project for patients diagnosed with NP-C
- RIS-INT-85 — Open-label Study Exploring a Switching Regimen From Depot Neuroleptics to Risperidone Depot Microspheres
- ET-B-017-99 — Phase 2 study of ET-743 as second or third line therapy in advanced and/or metastatic soft tissue sarcoma patients
- ET-B-010-99 — Phase II clinical trial of ET-743 as 2nd or 3rd line treatment in patients with advanced stage and/or metastatic soft tissue sarcoma
- ET-B-008-98 — Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
- ET-B-005-98 — Phase II study on ET-743 in advanced soft tissue sarcomas of the adult (excluding gastrointestinal stroma cell tumors – GIST)
- GAL-USA-10 — Placebo-controlled evaluation of galantamine in the treatment of Alzheimer’s disease: Evaluation of safety and efficacy under a slow titration regimen
- RIS-BEL-14 — Risperidone in the treatment of behavioural disturbances in patients with Alzheimer's dementia: a double-blind placebo-controlled trial
- RIS-USA-1 (RIS-USA-9001) — Risperidone versus haloperidol versus placebo in the treatment of schizophrenia
- RIS-USA-240 — The efficacy and safety of flexible dose ranges of risperidone vs. Placebo or divalproex sodium in the treatment of manic or mixed episodes associated with bipolar 1 disorder
- RIS-USA-72 — The safety and efficacy of risperidone 8 mg qd and 4 mg qd compared to placebo in the treatment of schizophrenia
- C0168T14 — Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
- 02-161 — Tolerability and Multiple-Dose Pharmacokinetics of Acetaminophen (Paracetamol) At and Above the Currently Recommended Maximum Daily Dose
- — Uni-Polar Depression Blood Gene Expression Study
Data Requests
- 2014-0291 — Comparative effectiveness of tumor necrosis factor alpha inhibitors in ankylosing spondylitis
- 2014-0317 — Risperidone for conduct problems: do improved indicators of emotional dysregulation mediate improved behavioral outcomes?
- 2014-0333 — RECIST response as a surrogate endpoint in metastatic castration-resistant prostate cancer: Retrospective analysis of COU-AA-302 and COU-AA-301
- 2014-0334 — Gender Differences in Weight Gain in Patients with Inflammatory Bowel Disease Treated with Infliximab
- 2014-0340 — The effects of SGLT-2 inhibitors in patients with type 2 diabetes: a systematic review with meta-analysis of randomised trials
- 2014-0364 — Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual patient level analyses of placebo-controlled trials
- 2014-0401 — Can Machine Learning Algorithms using General Labs Predict Biologic Remission for Patients on Thiopurines in the SONIC trial?
- 2015-0339 — Impact of the dose of immunomodulators on pharmacokinetics of biologics: Patient level meta-analysis of randomized controlled trials
- 2015-0416 — Bone safety of canagliflozin, aSGLT2 inhibitor, in type 2 diabetes: A retrospective analysis to evaluate fracture risk
- 2015-0500 — Studying the Risk of Harmful Drug-Drug Interactions (DDI) in Patients with Castration-Resistant Prostate Cancer (CRPC) Treated with Abiraterone (ABI)
- 2015-0514 — Comparison of 5-Day Course of Levofloxacin vs 10-Day Course of Ciprofloxacin Therapy in Males with Urinary Tract Infection
- 2015-0522 — Impact of infliximab concentrations on combination therapy for Crohn's disease
- 2015-0527 — Optimizing Infliximab in IBD: Developing a model to determine the optimal interval for monitoring infliximab concentrations
- 2015-0560 — Construct and Content Validity of Instruments Used in Clinical Trials of Psoriatic Arthritis
- 2015-0565 — Understanding reasons for screen failures in late phase trials in advanced GU cancers
- 2015-0587 — Estimating the effect of bedaquiline on MDR-TB culture conversion and treatment outcomes using marginal structural models
- 2015-0612 — Impact of Obesity on Disease Course and Response to Biologic Therapy in Inflammatory Bowel Disease: A Post-Hoc Analysis of RCTs
- 2015-0617 — Diagnostics for Informative Censoring in Efficacy and Effectiveness Trials of Schizophrenia Therapy
- 2015-0644 — Generalizing treatment effects for bipolar disorder and schizophrenia to the US population: Generalizability of network meta-analysis
- 2015-0649 — Population Representativeness of Clinical Trial Study Samples
- 2015-0676 — Investigating the construct validity of supersensitivity psychosis: An analysis of data from two antipsychotic discontinuation studies
- 2015-0677 — Meta-analysis: Duration of inflammatory bowel disease and its impact on efficacy of biologic drugs
- 2015-0678 — Heterogeneous Causal Effects: Drug Exposure & Safety
- 2015-0691 — Impact of Biologic Therapy on the Risk of Arterial and Venous Thromboembolic Events in Chronic Autoimmune Diseases: A Post-Hoc Analysis of RCTs
- 2016-0698 — Placebo response in rheumatoid arthritis
- 2016-0716 — Mediation Analysis to explain comparative efficacy of antipsychotic medications for treatment of schizophrenia in short-term RCT
- 2016-0725 — Investigation of Racial and Ethnic Differences in Cardiometabolic Health of Patients with Schizophrenia/Schizoaffective Disorder
- 2016-0734 — Safety of Bedaquiline (BDQ) in the treatment of multi-drug resistant tuberculosis: a protocol for an individual patient data meta-analysis
- 2016-0738 — Efficacy and safety of Sofosbuvir and Simeprevir for the Treatment of Chronic Hepatitis C genotype 4: a pooled analysis of existing data
- 2016-0765 — Improving the statistical analysis of cognitive outcomes in randomised controlled trials: The ?Optimising the Analysis of Cognition? Collaboration
- 2016-0766 — Gastrointestinal disease impact on antipsychotic induced weight gain and metabolic syndrome in schizophrenia: analysis of randomized controlled trials
- 2016-0767 — Determinants of treatment outcomes of multidrug-resistant tuberculosis (MDR-TB): an Individual Patient Data (IPD) Meta-Analysis - Update
- 2016-0774 — Individual patient data meta-analysis of four multicenter, randomized, controlled trials evaluating epoetin alfa in critically ill trauma patients
- 2016-0880 — Incidence of death and other SAEs related to second generation antipsychotic or placebo treatment in RCTs - a systematic review and meta-analysis
- 2016-0884 — A Meta-analysis of current treatments' efficacy for Relapsed Ovarian Cancer
- 2016-0897 — A systematic review and economic evaluation of certolizumab pegol and secukinumab for treating active psoriatic arthritis
- 2016-0903 — Use of TNF antagonist therapies with or without steroids for induction in Crohn?s disease: A Meta-analysis
- 2016-0912 — Reproduction analysis of the THERMOCOOL SMARTTOUCH? Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation trial
- 2016-0919 — Comparative efficacy of biologics in resolving extraintestinal manifestations of IBD: a systematic review and meta-analysis
- 2016-0960 — Bayesian Methods for Comparative Effectiveness Research
- 2016-0969 — Identifying individual factors predictive of extrapyramidal side effects (EPS) in Alzheimer's disease
- 2016-0979 — Predictors of radiographic progression in metastatic castration-resistant prostate cancer: Retrospective analysis of COU-AA-301
- 2016-0995 — Identifying the optimal target for Psoriatic Arthritis: a retrospective analysis to identify which target best predicts improved long term outcomes
- 2016-1005 — Identification of multivariate, clinical patterns predicting treatment response to paliperidone in schizophrenia
- 2016-1038 — Development and validation of historical control using placebo data from pediatric epilepsy studies
- 2016-1046 — Serum infliximab concentration and prevention of clinical or endoscopic post-operative recurrence after an ileocolonic resection for Crohn's disease
- 2016-1057 — Incidence of visceral metastasis at time of progression on abiraterone for metastatic castration-resistant prostate cancer
- 2016-1058 — Predictors of survival in metastatic castration-resistant prostate cancer
- 2016-1103 — The neutrophil to leukocyte ratio (NLR) in metastatic castrate resistant prostate cancer(mCRPC) patients treated with abiraterone acetate
- 2016-1107 — The impact of anti-TNF drug levels on rates of fistula healing in individuals with Crohn?s Disease
- 2016-1122 — Predictors of radiographic progression in metastatic castration-resistant prostate cancer: Retrospective analysis of COU-AA-302
- 2016-1136 — Impact of statins on outcomes in patients with castration resistant prostate cancer treated with abiraterone
- 2016-1171 — Predictors of Survival in a Trial of Abiraterone Acetate for Men with Metastatic Castration-Resistant Prostate Cancer and No Prior Chemotherapy
- 2016-1176 — Can Machine Learning Algorithms Using General Labs Predict Biologic Remission for Patients on ustekinumab?
- 2016-1196 — From clinical trials to routine care: understanding patient response to biologics in rheumatoid arthritis.
- 2017-1276 — Defining a therapeutic drug window in patients treated with infliximab for fistulizing Crohn?s disease.
- 2017-1356 — Does Body Mass Index predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer?
- 2017-1451 — Long-term Impact of Patient Global Assessment on radiographic damage and physical function in patients with RA in Remission vs "near-remission"
- 2017-1456 — The efficacy of biologic medications in improving depressive symptoms in patients with PsA ? Patient-level meta-analysis
- 2017-1466 — The use of clinical experimental data to build personalized medicine models and the evaluation of their effectiveness and statistical significance.
- 2017-1521 — Predictors of Relapse following Maintenance Treatment of Antipsychotic Drug or Placebo in patients with SCZ, schizoaffective disorder and BPD
- 2017-1671 — Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and IPD NMA
- 2017-1676 — Placebo Effects in Schizophrenia
- 2017-1701 — Response to Placebo Treatment and Non-response to Active Drug Treatment in Clinical Trials of Long-Acting Injectable Antipsychotics for Schizophrenia
- 2017-1706 — Comparison of ?real-life? clinical practice to clinical trials? a propensity score standardization method
- 2017-1746 — Heterogeneity in relative treatment efficacy by age, sex, socioeconomic status and comorbidity
- 2017-1816 — MASTERMIND: Stratification of response to SGLT2 inhibitor glucose lowering therapy
- 2017-1846 — Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
- 2017-1856 — Impact of Age on Safety and Efficacy of Biologic Therapy for Inflammatory Bowel Disease
- 2017-1861 — TESTING - Ginger
- 2017-1966 — Psychosis break through antipsychotic maintenance medication: An individual participant data meta-analysis
- 2017-2031 — Association between Patient-reported Outcomes and Endoscopic Healing in Ulcerative Colitis: A meta-analysis
- 2017-2036 — Determine the growth and regression rate constant and the fractional cell kill of abiraterone acetate in prostate cancer
- 2017-2306 — Continuing or Stopping 5-ASA in Biologic-Treated Patients with Moderate-Severe Ulcerative Colitis: A Post-Hoc Analysis of RCTs
- 2017-2326 — Development of a Global Outcome Measure for Rheumatoid Arthritis Clinical Trials
- 2017-2381 — Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of bDMARDs in patients with RA
- 2017-2486 — Neutropenia in myelosuppressed cancer patients treated with recombinant human erythropoietin (EPO)
- 2017-2511 — Policy-aware evaluation of personalized treatment strategies
- 2017-2651 — Do alpha blockers and 5-reductase inhibitors influence survival and urinary function in patients with castration resistant prostate cancer
- 2018-2686 — Exploring the impact of different analysis and extrapolation methods for time-to-event data on estimates of lifetime cost-effectiveness.
- 2018-2761 — Relationship between decreased bone mineral density and syndesmophyte development: a multilevel analysis in patients with Ankylosing Spondylitis
- 2018-2801 — Development and applications of new safety analysis methods for randomized clinical trials
- 2018-2931 — Influence of demographic and environmental factors on anti-TNF efficacy in rheumatoid arthritis: a systematic review and meta-analysis of RCT
- 2018-3011 — Clinical Significance and Factors Associated with PSA Progression in mCRPC Patients Treated with Abiraterone
- 2018-3051 — Dopamine supersensitivity psychosis in randomized controlled studies of long-acting injectable vs. oral agents of the same atypical antipsychotic
- 2018-3061 — Development of a Clinical Prediction Tool for Treatment Outcomes in Infliximab-treated Patients with Moderate-Severe Ulcerative Colitis
- 2018-3121 — Speed of onset of infliximab and golimumab in patients with moderate-severely active ulcerative colitis: A Post-Hoc Analysis of RCTs
- 2018-3126 — Concomitant 5-ASA in Biologic-Treated Patients with Moderate-Severe Crohn?s Disease: A Post-Hoc Analysis of RCTs
- 2018-3131 — Treatment outcomes with biologics in moderate-severely active Crohn's disease stratified by ileal vs. colonic disease location
- 2018-3156 — Pharmacokinetics in type 2 diabetes mellitus patients using bedaquiline for tuberculosis (PANDEMIC)
- 2018-3236 — Thiopurines versus anti-TNFa for the prevention of postoperative recurrence in Crohn?s disease ? a meta-analysis of individual patient data
- 2018-3321 — Evaluation of longitudinal serum M protein (or free light chain) to predict survival in patients with relapsed/refractory multiple myeloma
- 2018-3476 — Efficacy of Crohn?s Disease Treatment Stratified by Disease Phenotype
- 2018-3556 — Influence of Race and Ethnicity on the Efficacy of Biologic Drugs for Inflammatory Bowel Disease
- 2018-3704 — Identifying factors related to high placebo response rates in patients with active rheumatoid arthritis despite prior treatment with biological agents
- 2018-3737 — Gender-based Differences in Response to Therapy in Inflammatory Bowel Disease
- 2018-3743 — The impact of biological interventions on health?related quality of life in adults with Crohn's disease
- 2018-3745 — Association of Quality of Life Measures with Outcome in Metastatic Castration-resistant Prostate Cancer
- 2018-3765 — Predictors of therapeutic and adverse effect outcomes of golimumab
- 2018-3813 — External validation of a prognostic nomogram for first-line therapy in metastatic castration-resistant prostate cancer
- 2019-3821 — Variability in antipsychotic response
- 2019-3827 — Prediction of outcome and adverse events in antipsychotic treatment
- 2019-3829 — Predicting Individual Treatment Effects for Doxil/Caelyx in Malignant Ovarian Cancer
- 2019-3850 — A new randomization procedure: pairwise sequential randomization (PSR), properties and applications in both causal inference and clinical trials.
- 2019-3865 — Alternative Data Presentation For Treatment Outcomes in Psoriasis
- 2019-3886 — The relative efficacy and safety of enzalutamide, apalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer
- 2019-3893 — Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in patients with ankylosing spondylitis
- 2019-3936 — Unbiased Treatment Efficacy Detection Methods with Patient Centered Outcomes
- 2019-3938 — Machine learning prediction of remission in patients given augmented treatment in major depression
- 2019-3941 — Factors moderating estimates of antipsychotic efficacy in schizophrenia
- 2019-3943 — Defining a therapeutic drug window for infliximab induction therapy in pediatric patients with moderate-to-severe Crohn's disease
- 2019-3958 — Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- 2019-3978 — Safety of Risperidone and Paliperdone in schizophrenia and bipolar disorder diagnosed patients - a systematic review and meta-analysis
- 2019-3980 — Impact of Ulcer Size and Extent of Inflammation On Ability To Achieve Endoscopic Healing In Crohn's Disease: A SONIC post hoc Analysis
- 2019-3990 — Quality-of-life in men with castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review with meta-analyses
- 2019-3995 — Cardiovascular safety associated with SGLT-2 inhibitors across racial groups in patients with T2DM: a meta analysis and systematic review.
- 2019-3999 — Psychiatric Symptoms as Adverse Events of Abiraterone / Prednisolone Therapy: Systematic Review and Meta-Analysis
- 2019-4013 — Prognostic relevance of prior local therapy, time to metastasis and time to castration resistant prostate cancer (CRPC) in metastatic CRPC (mCRPC)
- 2019-4015 — Justification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development Tool Qualification in Rheumatoid Arthritis
- 2019-4026 — The Role of Fecal Calprotectin in Predicting Clinical Remission and Mucosal Healing in Crohn's Disease
- 2019-4035 — Exploration of regional heterogeneity in trials assessing the efficacy of recent non-insulin glucose lowering drugs on cardiovascular outcomes
- 2019-4066 — Assessment of treatment outcome with golimumab in nr-axSpA by baseline CRP
- 2019-4067 — Evidence-generation for biologics in pediatric studies
- 2019-4071 — Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes: systematic review incorporating unpublished clinical study reports
- 2019-4075 — Derivation and Validation of Predictive Models in an aggregated Pulmonary Arterial Hypertension cohort
- 2019-4077 — Evaluation of debiased machine learning methods to estimate the average treatment effect in observational studies.
- 2019-4078 — Consistency checks to improve measurement with the Personal and Social Performance (PSP) scale
- 2019-4080 — Explainable Artificial Intelligence Models for Personalized Prediction of Treatment Response in Neurobehavioral Disorders
- 2019-4090 — Association of Health Related Quality of Life variations with biological biomarkers for patients with metastatic castrate resistant prostate cancer
- 2019-4092 — Cross-Trial Comparisons of Biologic Therapies for Auto-Immune Diseases
- 2019-4093 — GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes. A systematic review and meta-analysis
- 2019-4104 — Effectiveness of Ustekinumab on Arthritis/Arthralgia in Crohn's Disease: post hoc Analysis of UNITI
- 2019-4105 — The Impact of Body Mass Index on the Efficacy of Ustekinumab in the IM-UNITI Trial
- 2019-4107 — Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: individual-patient level meta-analysis
- 2019-4134 — Systematic review and individual participant data meta-analyses of systemic treatments for hormone-sensitive metastatic prostate cancer
- 2019-4146 — Evaluation of exogenous glucocorticoid potencies
- 2020-4165 — Exploring Novel Methods to Estimate Heterogeneous Treatment Effects
- 2020-4175 — Placebo relapse after antipsychotic withdrawal: an individual participant meta-analysis
- 2020-4189 — Design and validation of an external control arm using prior clinical trials and real-world data
- 2020-4211 — The effect of SGLT2 inhibitors in diabetes subgroups identified by data-driven clustering
- 2020-4213 — Validation of a Machine Learning-based Model to Predict the Risk of Heart Failure among Patients with Diabetes Mellitus: the WATCH-DM Risk Score
- 2020-4215 — A systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosis
- 2020-4231 — A systematic review and individual patient data meta-analysis of blood biomarkers in idiopathic pulmonary fibrosis
- 2020-4234 — Patient Reported Outcomes in Crohn?s Disease: A Post-hoc Analysis of the SONIC Trial
- 2020-4236 — The blood pressure increases related to ibrutinib treatment: post-hoc analysis of an RCT.
- 2020-4244 — Cardiorenal outcomes of second-line antidiabetic drugs in patients with Type 2 diabetes: a systematic review and network meta-analysis
- 2020-4275 — Machine Learning Applications for Improving the Efficiency of Clinical Trials in Alzheimer's Disease
- 2020-4276 — Psychiatric Symptoms as Adverse Events of Topiramate Therapy: Systematic Review and Meta-Analysis
- 2020-4298 — PSA Progression in High-Risk Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- 2020-4299 — Impact of Daratumumab on the Risk of Venous Thromboembolism in Patients with Multiple Myeloma: A Post-hoc Analysis of Phase III trials
- 2020-4305 — A predictive model to guide safer risperidone prescribing in people with Alzheimer?s disease
- 2020-4310 — A Data-Zone Scoring System to Assess the Generalizability of Canagliflozin to Individual Patients
- 2020-4311 — The neutrophil to leukocyte ratio(NLR) as a biomarker in metastatic castrate sensitive prostate cancer(mCRPC) patients treated with abiraterone
- 2020-4317 — A new fixed-effects approach for validation of a longitudinally measured surrogate biomarker for a time-to-event endpoint
- 2020-4318 — Enhancing inference from real-world data using externally-derived missing data models: a pilot study of Ulcerative Colitis
- 2020-4323 — Identification of biomarkers associated with Alzheimer?s disease progression that correlate with responses to medications.
- 2020-4324 — Meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in AD, PD and DLB
- 2020-4341 — Estimating the association between TNF inhibitors and Legionnaires' disease and Listeriosis: A Meta-analysis
- 2020-4362 — Impact of Baseline Strictures on Clinical and Endoscopic Outcomes in Crohn's Disease
- 2020-4363 — Predictors of Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI and IM-UNITI Trials
- 2020-4386 — Pharmacometric models on lymphocyte dynamics, lymph node size and blood pressure linked to survival in CLL patients treated with ibrutinib
- 2020-4390 — A novel statistical approach to detect the efficacy of drugs that have heterogeneous treatment effects
- 2020-4409 — Canagliflozin and Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes (CaNAFLD) A Post-Hoc Analysis of RCTs
- 2020-4413 — Creatinine kinase levels among concomitant statin and SGLT2 use
- 2020-4415 — Development and assessment of Virtual Cohorts derived from historical Pulmonary Arterial Hypertension clinical trials.
- 2020-4416 — Comparative Efficacy of Ustekinumab and Infliximab on Clinical and Endoscopic Outcomes in Crohn?s Disease
- 2020-4417 — Vibration of effects in pooled analyses of Canagliflozin vs placebo, randomized, double blind trials
- 2020-4442 — Add-on treatment for refractory focal-onset epilepsy: Individual Participant Data Network Meta-Analysis
- 2020-4444 — Expectancy Effects as a Confounding Factor in ADHD Treatment Research
- 2020-4448 — Reanalysis of Alzheimer?s Disease Clinical Trials Using Longitudinal Latent Trait Models
- 2020-4453 — Data-Adaptive Weighting of Real-World and Randomized Controls Using Propensity Scores: Creating a Hybrid Control Arm
- 2020-4454 — Inferential reproducibility of therapeutic research: a registered report for a cross-sectional study of RCTs available on major data-sharing platforms
- 2020-4457 — Comparative Effectiveness of Vedolizumab vs. Infliximab in Ulcerative Colitis
- 2020-4465 — Examination of implications of acute declines in kidney function with SGLTII inhibitors
- 2020-4474 — Comparison of the Rutgeert's score with the SES-CD for prediction of post-operative clinical recurrence in Crohn?s disease
- 2020-4488 — Mediators between Canagliflozin and End-stage kidney disease: Post-hoc mediation analyses of the CREDENCE trial
- 2020-4499 — Serum cytokines in predicting outcomes to ustekinumab in patients with Crohn?s disease
- 2020-4517 — Metabolic side effects of antipsychotic drugs during medium- to long-term treatment in schizophrenia: Systematic review and network meta-analysis
- 2020-4521 — Causally interpretable meta-analysis with missing data: Generalizing evidence from bipolar disorder and schizophrenia trials to a target population
- 2020-4528 — Validation of a shortened PANSS for use in clinical trials of adolescent schizophrenia.
- 2020-4529 — Endoscopic Disease Severity and Patient Reported Outcomes in Crohn's Disease
- 2020-4535 — Development of a Novel Disease Activity Index for Crohn?s Disease
- 2020-4548 — Getting new insight out of failed AD trials
- 2020-4553 — Exploring heterogeneity in the cardiovascular and renal benefits of canagliflozin in type 2 diabetes mellitus
- 2021-4565 — Prognostic Indicators in High-Risk Metastatic Castrate Sensitive Prostate Cancer
- 2021-4566 — Association of Quality-of-Life Parameters with Survival Outcomes in High-Risk Metastatic Castrate Sensitive Prostate Cancer
- 2021-4567 — Optimizing Trial design to Achieve Personalized prevention of Alzheimer?s disease
- 2021-4568 — Motor side effects and antipsychotic efficacy of antipsychotic drugs: An individual participant meta-analysis
- 2021-4571 — Risk factors of DU and related outcomes from post-hoc Analyses of the DUAL-1 & DUAL 2 RCTs In the YODA project : the DADDI YODA project
- 2021-4575 — A NOVEL METHOD TO SUMMARIZE SAFETY IN CLINICAL TRIALS USING PHARMACOLOGICAL CLASS-RELATED RISKS IN FAERS
- 2021-4599 — Outcomes with Early versus Late Response to Daratumumab in Patients with Refractory/Relapsed or Newly Diagnosed Multiple Myeloma
- 2021-4602 — Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohn's Disease
- 2021-4620 — The effects of antipsychotic discontinuation and reinstatement
- 2021-4637 — Data-sharing and re-analysis for main studies assessed by the European Medicines Agency - a cross-sectional study on EPARs
- 2021-4638 — Impact of frailty on outcomes of patients treated with Daratumumab, Lenalidomide and Dexamethasone for newly diagnosed Multiple Myeloma
- 2021-4640 — An individual patient data meta-analysis of daratumumab in the treatment of different cytogenetic subsets of multiple myeloma
- 2021-4649 — A statistical methodology study to evaluate External Comparator Arm study results versus Randomized Controlled Trials in cancer drug development
- 2021-4658 — Ketamine for the treatment of major depression: a systematic review and meta-analysis
- 2021-4660 — Associations between response, progression, and overall survival in phase III daratumumab clinical trials in relapsed/refractory multiple myeloma
- 2021-4663 — Thromboembolism Prophylaxis and the Incidence of Venous Thromboembolism in Newly Diagnosed Multiple Myeloma Patients Enrolled on the MAIA trial
- 2021-4666 — Elucidation of the predictive factors for active and placebo drug response on social functioning and QOL in psychiatric illnesses
- 2021-4667 — Estimation of Geographic and Demographic Variabilities Associated with Schizophrenia Age of Onset and Duration of Untreated Psychosis
- 2021-4683 — The effects of systemic anti-infective concomitant medications on progression of neurological diseases
- 2021-4684 — Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn's Disease
- 2021-4698 — Early clinical response to biologics and small molecules for moderate-to-severe ulcerative colitis: a network meta-analysis
- 2021-4705 — Inflammation and the Metabolic Syndrome in Psychosis
- 2021-4712 — Real time monitoring of individual response to antiseizure medication treatment during clinical trials
- 2021-4715 — Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis incorporating individual patient data
- 2021-4740 — The Impact of Second Generation Anti-Androgens on Sexual Function in Men with Advanced Prostate Cancer
- 2021-4741 — Intrathecal Adrabetadex for Niemann-Pick Type C (NPC): Case Control Study in Early Onset NPC and Comparison of Natural History and Treated Cohorts
- 2021-4754 — Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
- 2021-4757 — A Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis.
- 2021-4758 — Examining the relationship between esketamine-induced dissociation and antidepressant effects
- 2021-4764 — Reporting of harms in SGLT2 clinical study reports compared to trial registries and publications: a methodological review
- 2021-4766 — Early Prediction of Treatment Response to Antipsychotics for Irritability and Aggression in Autism Spectrum Disorder
- 2021-4770 — Indirect comparison of daratumumab-based regimen versus bortezomib, lenalidomide, and dexamethasone for newly diagnosed, transplant ineligible MM
- 2021-4777 — Adverse Events of Special Interest (AESI) Predict Response to Abiraterone Acetate (AA): A Retrospective Analysis
- 2021-4778 — Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease
- 2021-4779 — Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn's Disease
- 2021-4812 — Effects of new antidiabetic agents on cardiovascular outcomes in older adults: systemic review and meta-analysis
- 2021-4813 — Association between proton pump inhibitor use and survival of patients with prostate cancer receiving abiraterone acetate plus prednisone
- 2021-4818 — Rapidity of Symptom Improvement with Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-analysis
- 2021-4819 — Progression Free Survival and Mutation Landscape between Eastern and Western de novo Metastatic Prostate Cancer
- 2021-4821 — Evaluation of a single global item for side effect bother
- 2021-4822 — Comparative Efficacy of Ustekinumab and Infliximab on One Year Outcomes Among Biologic-nave Induction Responders in Crohn's Disease
- 2021-4823 — Long term risk for relapse in patients suffering from schizophrenia randomized to oral placebo - A historical prospective study
- 2021-4829 — Placebo Rates in Inflammatory Bowel Disease: An Individual Patient Data Meta-analysis of Randomized Controlled Trials
- 2021-4835 — Role of clinical, historical and demographic factors in the response to antidepressants versus placebo
- 2021-4836 — Adverse events of acetylcholinesterase inhibitors - systematic review and meta-analysis of double-blind randomized controlled trials
- 2021-4844 — Clinical predictors of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis
- 2021-4848 — Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis
- 2021-4849 — Minimax regret for data analysis with application to clinical treatment decisions
- 2021-4850 — Cluster Analysis of Cardiovascular Phenotypes and SGLT2 Inhibition in Patients With Type 2 Diabetes and Established Cardiovascular Disease
- 2021-4851 — Efficacy of esketamine for "treatment resistant depression" assessed by MADRS score after at least 4 weeks, an IPD meta-analysis
- 2022-4854 — Combining data sources to identify effect moderation for personalized mental health treatment
- 2022-4868 — Comparison of Outcomes in Patients treated with prior radical prostatectomy versus prior radiation therapy: a pooled analysis of ACIS and COU-AA302
- 2022-4869 — Using Electronic Health Records to derive a Synthetic Control Arm for a historical trial on Relapsed/Refractory Multiple Myeloma
- 2022-4882 — Impact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative Colitis
- 2022-4888 — Dose reduction and discontinuation of disease modifying anti-rheumatic drugs (DMARDs) for juvenile idiopathic arthritis
- 2022-4889 — Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials
- 2022-4894 — Systemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of RCTs
- 2022-4895 — Co-designing a resource sheet to aid Prostate Cancer patient?s interpretation of PRO data from a clinical trial: Asynchronous online patient study
- 2022-4901 — A Prediction Model for Loss of Response in Ulcerative Colitis Patients Initially Responding to Infliximab Therapy After Induction.
- 2022-4928 — Ibrutinib plus rituximab versus ibrutinib monotherapy in patients with Waldenstrm macroglobulinemia: A pooled analysis of prospective studies
- 2022-4942 — External Validation of a Prognostic Model of Metastasis-Free Survival In Men with Nonmetastatic Castration-Resistant Prostate Cancer
- 2022-4949 — Precision Medicine for Patients with Ulcerative Colitis Using Synthetic Controls
- 2022-4951 — What are the re-identification risk scores of publicly available anonymised clinical trial datasets?
- 2022-4952 — Topiramate versus oral gepants in the treatment of patients with migraine: a matching adjusted indirect comparison
- 2022-4960 — Patient-reported Symptoms, Endoscopic, and Histologic Predictors of Endoscopic Improvement in Ulcerative Colitis
- 2022-4961 — Efficacy and safety of tumor necrosis factor inhibitors (TNFi) in seronegative rheumatoid arthritis patients who are inadequate responders to csDMARDs
- 2022-4962 — SPondyloarthritis: EARly Definition (ASAS-SPEAR): Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials
- 2022-4974 — Association between adverse events and change in quality-of-life scores in phase II-III cancer clinical trials
- 2022-4975 — Impact of concomitant baseline medication on efficacy of biologics and small molecules for Inflammatory Bowel Disease
- 2022-4981 — Efficacy of medical therapies for ulcerative colitis according to disease distribution: An individual patient data meta-analysis of RCTs
- 2022-4992 — Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2022-4996 — Risk stratification and responder identification for GLP-1RA and SGLT2i in T2DM: application of two machine learning based prediction models
- 2022-5008 — Analytical Approaches of Time to Event of Patient-reported Outcomes: A Case Study in Patients with Metastatic Castration-resistant Prostate Cancer
- 2022-5012 — The Relationship between The Time to Achieve Clinical or Biomarker Remission and Long-term Outcomes in Inflammatory Bowel Disease
- 2022-5013 — Identification of the Need for Hematopoietic Stem Cell Transplantation in Crohn's Disease Patients: A Ma-chine Learning Approach
- 2022-5021 — Correlation Between Symptoms and Objective Measures of Disease Activity in Patients with Moderate to Severe Ulcerative Colitis and Crohn?s Disease
- 2022-5027 — Development of a prognostic calculator for patients with metastatic prostate cancer undergoing treatment with androgen receptor axis-targeted therapy.
- 2022-5030 — Overall Survival and Radiographic Progression Free Survival difference among Asian, White and Black mCRPC patients treated with Abiraterone
- 2022-5036 — Proof-of-Concept study of a patient selection algorithm for disease modifying treatments in Alzheimer?s disease
- 2022-5037 — Estimating Differences in the Comparison of Outcomes in Clinical Trials for UC Patients using Patient-Level Data and Aggregated Data: Network Meta-Ana
- 2022-5039 — An evaluation of the performance of two population-adjusted indirect comparison methods in anchored and unanchored settings
- 2022-5048 — Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma
- 2022-5056 — Predicting response under hypothetical interventions in patients with rheumatoid arthritis: a methodological exploration
- 2022-5058 — The impact of long-term proton pump inhibitors use on the prognosis of patients receiving Androgen-annihilation therapy.
- 2022-5060 — A meta-analysis to assess relationships between patient demographics and response to antibody-based treatment in rheumatoid arthritis patients
- 2022-5062 — Heterogeneous treatment effects estimation with multi-source data: evidence from bipolar disorder and schizophrenia trials
- 2022-5066 — Predictors of exposure, therapeutic and adverse effects of ibrutinib used in the treatment of B-cell lymphomas
- 2022-5067 — Predictive Value of QT Interval Dispersion in Patients with Pulmonary Arterial Hypertension (PAH)
- 2022-5070 — An individual patient data meta-analysis of clinical endpoints in pulmonary hypertension with interstitial lung disease (ILD-PH)
- 2022-5076 — The efficacy of canagliflozin in diabetes subgroups by using an unsupervised machine-learning method
- 2022-5080 — Validating a Personalised Ankylosing Spondylitis Metrology Index.
- 2022-5090 — Consistency checks to improve measurement with the Young Mania Rating Scale (YMRS)
- 2022-5091 — Consistency checks to improve measurement with the Cohen Mansfield Agitation Inventory (CMAI)
- 2022-5100 — Identification of Patients Who Can Benefit from Intracranial Stent Placement: analysis of Vitesse Intracranial Stent Study for Ischemic Stroke Therapy
- 2022-5102 — Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis incorporating individual patient data
- 2022-5104 — Biomarkers for Predicting Long-term Outcomes in Ulcerative Colitis
- 2022-5105 — Symptom severity and minimal clinically important differences for agitation outcome scores in Alzheimer's disease clinical trials
- 2022-5106 — Assessing the Androgen indifferent prostate cancer patients response to novel antiandrogen-based regimen or taxanes
- 2022-5108 — Personalized prediction of PFS in myeloma patients treated with DaraPomDex or Pom-Dex alone, using combined machine learning and mechanistic modeling
- 2022-5120 — Validation of an artificial intelligence model on central read endoscopic disease severity in patients with ulcerative colitis
- 2022-5123 — CYP3A4 Interactions and Adverse Drug Reactions in Ibrutinib Therapy: Revisting multiple clinical trials
- 2022-5124 — Understanding frailty, multimorbidity and renal failure in clinical trials: Attrition, retention and heterogeneity of treatment effects in trials
- 2022-5125 — Risk of therapy-related adverse events in men on abiraterone or enzalutamide, a meta-analysis of clinical trial data
- 2023-5137 — Impact of Prior Local Therapy on Outcome in Men with non-metastatic Castrate Resistant Prostate Cancer
- 2023-5145 — Improving efficiency of immune-mediated inflammatory disease trials through better design and analysis
- 2023-5149 — Sex Differences in the Antidepressant Effects of Ketamine
- 2023-5158 — Predicting treatment response to adalimumab and ustekinumab using the MM-SES-CD in Crohn's disease
- 2023-5162 — Is minimal residual disease a valid surrogate endpoint for survival in multiple myeloma?
- 2023-5173 — Improving Outcome in Advanced Prostate Cancer: a Pooled Analysis of Randomized Controlled Trials
- 2023-5187 — The association between antibiotics exposure and outcomes in men with prostate cancer
- 2023-5194 — Determining Endoscopic Treatment Response in Ulcerative Colitis and Crohn's Disease using the Win Probability Approach
- 2023-5197 — Allostatic Load, Treatment Outcomes, and Mortality in Transplant-Ineligible Patients with Multiple Myeloma
- 2023-5198 — Evaluation of G-computation and conformal prediction to provide early signs of efficacy in single arm trial with time to event outcomes
- 2023-5217 — Biomarkers for predicting long-term outcomes in ulcerative colitis
- 2023-5218 — ARIA detection, predictability, and relationship to treatment response
- 2023-5226 — Time to Event Designs for Epilepsy
- 2023-5230 — Esketamine for treatment-resistant depression in adults: Cochrane systematic review and meta-analysis on efficacy and tolerability of esketamine
- 2023-5235 — Bone modifying agent in treatment of patients with metastatic castration-sensitive prostate cancer
- 2023-5236 — Understanding the Symptom Experience of Abiraterone and the Effect on Quality of Life for Men with metastatic Prostate Cancer.
- 2023-5241 — Cognitive effects of repeated-dose Ketamine in the treatment of major depression: a systematic review and individual patient data meta-analysis.
- 2023-5242 — Patterns of disease progression in patients with metastatic, castration-sensitive prostate cancer
- 2023-5247 — Identifying Prognostic and Predictive Factors for Causal Exposure-Response Analysis of Ibrutinib in treatment of non-Hodgkin Lymphoma
- 2023-5251 — Efficient Learning of Continuous-Time Hidden Markov Models with Discrete-Time Irregular Observations for Healthcare Intervention Planning
- 2023-5254 — Identifying Prognostic and Predictive Factors for Causal Dose-Response Analysis of Daratumumab in Multiple Myeloma
- 2023-5274 — Statin use and outcomes in patients treated in the SPARTAN, TITAN and ACIS trial
- 2023-5290 — The Impact of Dose Timing on the Efficacy and Safety of Abiraterone Acetate plus Prednisone in Men with Advanced Prostate Cancer
- 2023-5295 — Individual-level and study-level predictors of neuropsychiatric symptom placebo response in Alzheimer?s Disease clinical trials
- 2023-5300 — Outcomes from induction using ustekinumab or vedolizumab among patients who have prior biologic intolerance vs biologic failure in UC and CD
- 2023-5316 — Prospective Assessment of ISS-R2 as a Prognostic Indicator in Patients with Newly Diagnosed Multiple Myeloma in the Anti-CD38 Era
- 2023-5337 — Characterisation of patients with pulmonary sarcoidosis
- 2023-5341 — Personalized dosing of golimumab based on serum drug concentrations in patients with rheumatoid arthritis
- 2023-5353 — Safety and tolerability of conventional MDR-TB regimens
- 2023-5354 — Effectiveness of Intranasal Esketamine in the Treatment of Patients with Treatment Resistant Depression: An Observational Study Based on Data Collected in a Spravato Treatment Program at the Institute of Living
- 2023-5367 — Efficacy and safety of canagliflozin in diabetic patients with erythrocytosis: A pooled analysis of the CANVAS Program and CREDENCE trial
- 2023-5502 — Development of a model to simulate the pharmacokinetics of drugs in patients with different characteristics to advance precision medicine
- 2024-0008 — Sex differences in antipsychotic efficacy and side-effects in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
- 2024-0052 — Generalizability of clinical prediction models using synthetic data generated through random sampling
- 2024-0056 — Multi-study causal inference for robust clinical outcome predictions
- 2024-0060 — Using Synthetic Controls to Improve Randomised Controlled Trials for Rare Diseases
- 2024-0316 — Monthly test of form functionality
